Literature DB >> 19224412

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.

Robert Paul1, Nadine Schaaff, Frank Padberg, Hans-Jürgen Möller, Thomas Frodl.   

Abstract

Recent studies with intravenous infusion of the NMDA receptor antagonist ketamine showed robust and rapid antidepressant effects within hours after treatment. Ketamine is a racemic mixture consisting of two enantiomers, R- and S-ketamine. In contrast to ketamine, S-ketamine is reported to be less prone to psychomimetic side effects, such as derealisation and hallucinations. In this report we describe the effect of ketamine and S-ketamine infusion therapy, respectively, in two patients with treatment-resistant major depression. Severity of depression was rated using the Hamilton Depression Rating Scale (HAMD) and the Beck Depression Inventory (BDI). While one patient did not respond to either treatment, in the other patient intravenous administration of ketamine as well as S-ketamine showed an antidepressant effect as assessed by a decrease in HAMD-21 and BDI at days 1 and 3 after infusion which faded until day 6. Both patients experienced psychomimetic side effects during ketamine infusion which were absent during treatment with S-ketamine. We conclude that S-ketamine might exert similar antidepressant effects as ketamine in drug-resistant depression but may be better tolerated by the patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19224412     DOI: 10.1080/15622970701714370

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  25 in total

Review 1.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 2.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

3.  Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.

Authors:  Eric J Lenze; Nuri B Farber; Evan Kharasch; Julie Schweiger; Michael Yingling; John Olney; John W Newcomer
Journal:  World J Biol Psychiatry       Date:  2016-02-26       Impact factor: 4.132

4.  [Ketamine for treatment of therapy-resistant depression: a case study].

Authors:  F Segmiller; D Frisse; D Eser; H-J Möller; T Rüther; C Schüle
Journal:  Nervenarzt       Date:  2013-07       Impact factor: 1.214

5.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

6.  Promises and Pitfalls of NMDA Receptor Antagonists in Treating Violent Aggression.

Authors:  Caitlyn J Bartsch; Jacob C Nordman
Journal:  Front Behav Neurosci       Date:  2022-06-21       Impact factor: 3.617

7.  Opposing effects of NMDA receptor antagonists on early life stress-induced aggression in mice.

Authors:  Jacob C Nordman; Caitlyn J Bartsch; Zheng Li
Journal:  Aggress Behav       Date:  2022-02-04       Impact factor: 3.047

8.  Innovative approaches to treatment - refractory depression: The ketamine story.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2010-04       Impact factor: 1.759

Review 9.  Current status of ketamine and related compounds for depression.

Authors:  Daniel C Mathews; Carlos A Zarate
Journal:  J Clin Psychiatry       Date:  2013-05       Impact factor: 4.384

10.  The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats.

Authors:  Ruin Moaddel; Mitesh Sanghvi; Katina Sourou Sylvestre Dossou; Anuradha Ramamoorthy; Carol Green; James Bupp; Robert Swezey; Kathleen O'Loughlin; Irving W Wainer
Journal:  Pharmacol Res Perspect       Date:  2015-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.